Literature DB >> 7470623

Procoagulant activity of sarcoma sublines with different metastatic potential.

M Colucci, R Giavazzi, G Alessandri, N Semeraro, A Mantovani, M B Donati.   

Abstract

It has been suggested that cancer cell procoagulant activity influences metastasis formation by promoting fibrin deposition around tumors. We have investigated the procoagulant activity of various tumor cell sublines with different metastatic capacity derived from metastatic nodules of a murine fibrosarcoma. All the cells tested possessed a marked thromboplastin-like activity; they were, however, heterogeneous as regards the degree of procoagulant activity; the two cell lines with virtually no metastatic capacity showed 6--8 times higher procoagulant activity than the cells from the parent line; in contrast, the procoagulant activity of the two sublines with higher metastatic capacity did not differ significantly from that of the parent line. These findings support the hypothesis that fibrin is part of a defence reaction against cancer cell invasiveness.

Entities:  

Mesh:

Year:  1981        PMID: 7470623

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Thrombin: implications for intratumor therapy against metastasis.

Authors:  A V D'Amico; A C Nelson; R K Babayan
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 2.  Studies on rat mammary adenocarcinomas: a model for metastasis.

Authors:  I A Ramshaw; P Badenoch-Jones
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 3.  Role of plasma, platelets, and endothelial cells in tumor metastasis.

Authors:  G J Gasic
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

4.  DMSO-induced changes in the procoagulant and fibrinolytic activity of B16 melanoma cells: influence on lung colony formation.

Authors:  B Casali; M G Lampugnani; M Riganti; A Niewiarowska; G Alessio; L Mussoni; N Semeraro; M B Donati
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.